Archive · 21 Aug 2026
Lupin Arm Licenses Yuvezzi Marketing Rights From Visus
Lupin is a large medicine company.
Its subsidiary, VISUfarma, made a deal with Visus Therapeutics.
The deal is about a product called Yuvezzi.
Yuvezzi is an eye medicine for adults who cannot see things clearly up close.
VISUfarma will handle approvals, marketing and sales in certain countries.
The agreement gives VISUfarma exclusive rights in those markets.
Visus Therapeutics belongs entirely to Tenpoint Therapeutics Holding.
The announcement was made on Thursday in New Delhi.
Lupin’s wholly owned arm VISUfarma BV signed an exclusive licensing agreement with Visus Therapeutics Inc.
The agreement covers commercialization of Yuvezzi in specified global markets.
Yuvezzi is an ophthalmic product for adults experiencing loss of clear close-up vision.
VISUfarma will receive exclusive rights for regulatory activities, commercialization and marketing.
Visus Therapeutics is a wholly owned arm of Tenpoint Therapeutics Holding Ltd.
- Who
- Lupin Ltd’s wholly owned arm VISUfarma BV and Visus Therapeutics Inc.
- What
- They entered an exclusive licensing agreement for VISUfarma to commercialize Yuvezzi.
- When
- The agreement was announced on Thursday.
- Where
- The rights cover specified global markets; the announcement was made in New Delhi.
- Why
- To commercialize, market and undertake regulatory activities for Yuvezzi, an ophthalmic product for adults with loss of clear close-up vision.
- Product
- Yuvezzi
- Product type
- Ophthalmic product
- Indication
- Loss of clear close-up vision in adults
- Lupin entity
- VISUfarma BV
- Licensing partner
- Visus Therapeutics Inc
- Territory
- Specified global markets
- Exclusive rights
- Regulatory activities, commercialization and marketing